FDA Expands Approval of AJOVY as First Anti-CGRP Preventive for Pediatric Episodic Migraine Read more
FDA Approves Jazz Pharma’s Modeyso as First Treatment for Recurrent H3 K27M-Mutant Brain Cancer Read more
The 3rd Spatial Biology for Drug Development Summit – *Free to Attend for Biopharma Experts Read more
FDA Accepts Bristol Myers Squibb’s Priority Review for Breyanzi in Relapsed/Refractory Marginal Zone Lymphoma Read more